School of Chemistry - Business Partnership Unit
  • Print
   
   

Spin-out Companies

 

dreamstime_xl_49151860 740 pxs 

Critical Pharmaceuticals Limited

 

Based on ground-breaking research by Prof Steve Howdle, Critical Pharmaceuticals uses its supercritical fluid technologies to formulate drugs and drug candidates within biodegradable polymers for controlled release applications. 

The first spin out company based on the School of Chemistry's research, Critical Pharmaceuticals was formed in 2002 and has since won numerous awards for innovation. Critical Pharmaceuticals has two proprietary technologies, which have entered clinical trials, are being developed as treatments for a number of medical conditions, including human growth hormone deficiency, schizophrenia and osteoporosis.

Critical Pharmaceuticals Logo

 

 

Promethean Particles

 

Promethean Particles Logo

Promethean Particles was spun-out in 2008 based on a collaboration between Prof. Martyn Poliakoff in the School of Chemistry and Dr Ed Lester from the Faculty of Engineering. Promethean Particles uses ground-breaking supercritical water (scH2O) technology to produce nanoparticles with close control over their composition, size, shape, morphology and properties. The company secured a second round of funding in 2012, allowing them to move into new, larger facilities across the road from the University in Nottingham’s Science Park. They are currently building commercial scale nanoparticle manufacturing capabilities funded through the EU FP7 SHYMAN project. By developing bespoke products with their commercial partners, Promethean Particles supply into a wide range of different industries.
 

 

QGenta

 

 

Qgenta is a spin-out company domiciled in Colorado, USA which has resulted from successful collaborative research between the Universities of Nottingham and the University of Colorado. A series of novel compounds developed by Prof. Chris Moody in the School of Chemistry at Nottingham and Prof David Ross and Dr David Siegel at Colorado have shown potential as the basis of future therapies for the treatment of solid tumours and in particular pancreatic cancers. Qgenta will provide a focus for rapid development and testing of these compounds and take them forward commercially. 

 

Logo for QGenta

 

Contact the BPU

 

 

 

 

Business Partnership Unit

School of Chemistry
University Park Nottingham, NG7 2RD

telephone: +44 (0) 115 74 86268
email: nottinghamanalytical@nottingham.ac.uk